Conflict of interest: Nothing to report
E-ONLY: Coronary Artery Disease
Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis
Article first published online: 4 MAY 2012
Copyright © 2012 Wiley Periodicals, Inc.
Catheterization and Cardiovascular Interventions
Volume 81, Issue 2, pages E124–E129, February 2013
How to Cite
Zago, A. C., Raudales, J. C., Attizzani, G., Matte, B. S., Yamamoto, G. I., Balvedi, J. A., Nascimento, L., Kosachenco, B. G., Centeno, P. R. and Zago, A. J. (2013), Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis. Cathet. Cardiovasc. Intervent., 81: E124–E129. doi: 10.1002/ccd.24331
Means followed by different letters indicate a statistically significant difference between groups after multiple comparisons by the Tukey test. P values were obtained from ANOVA and refer to the overall comparison of all four groups.
- Issue published online: 19 FEB 2013
- Article first published online: 4 MAY 2012
- Manuscript Accepted: 7 JAN 2012
- Manuscript Received: 2 AUG 2011
- in-stent restenosis
To test the local delivery of sirolimus nanoparticles following percutaneous transluminal coronary angioplasty (PTCA) to treat in-stent restenosis (ISR) in a swine model.
Coronary bare-metal stent (BMS) implantation reduces major adverse cardiac events when compared with PTCA; however, ISR rates remain high.
Eighteen swine underwent BMS deployment guided by intravascular ultrasound (IVUS). Of these, 16 developed ISR (1 stent/swine) and underwent angioplasty with a noncompliant balloon (PTCA-NC). The animals were then randomized into four groups for local infusion of sirolimus nanoparticles through a porous balloon catheter, as follows: (1) PTCA-NC alone (control); (2) PTCA-NC + (polylactic acid)-based nanoparticle formulation (anionic 1); (3) PTCA-NC + (polylactic-co-glycolic acid)-based nanoparticle formulation (anionic 2); and (4) PTCA-NC + Eudragit RS nanoparticle formulation (cationic). Coronary angiography and IVUS follow-up were performed 28 days after ISR treatment.
There was one episode of acute coronary occlusion with the cationic formulation. Late area loss was similar in all groups at 28 days according to IVUS. However, luminal volume loss (control = 20.7%, anionic 1 = 4.0%, anionic 2 = 6.7%, cationic = 9.6%; P = 0.01) and neointimal volume gain (control = 68.7%, anionic 1 = 17.4%, anionic 2 = 29.5%, cationic = 31.2%; P = 0.019) were significantly reduced in all treatment groups, especially in anionic 1.
PTCA-NC followed by local infusion of sirolimus nanoparticles was safe and efficacious to reduce neointima in this model, and this strategy may be a promising treatment for BMS ISR. Further studies are required to validate this method in humans. © 2012 Wiley Periodicals, Inc.